JRBF, General Genomics and WashU Medicine launch AI platform for NF1 research

The Joanna Ruth Bell Foundation, Curo 46 and Washington University School of Medicine are teaming up on an AI-enabled multi-omics platform for Neurofibromatosis Type 1 research. The effort aims to improve patient stratification, biomarker discovery and precision medicine for a rare disease with limited treatment options.

Why it matters: - The collaboration is built to speed up NF1 research by connecting clinical, imaging, genomic and biomarker data in one governed platform. - Better data integration could help researchers identify biomarkers earlier, model disease more accurately and design more precise clinical trials. - NF1 patients and families could ultimately benefit from improved stratification, stronger therapeutic development and more targeted care.

What happened: - The Joanna Ruth Bell Foundation, Curo 46, LLC, a General Genomics Inc. company, and Washington University School of Medicine in St. Louis announced a strategic collaboration on June 9, 2026. - The group will develop an AI-enabled clinical, genomic, imaging and multi-omics data platform for Neurofibromatosis Type 1 research. - The announcement was made in Oxford, United Kingdom.

The details: - JRBF will lead patient-centered stewardship and community engagement. - Curo 46 will provide AI and data integration capabilities. - WashU Medicine will contribute biomedical informatics, clinical research and responsible health AI expertise. - The platform is intended to support disease modeling, biomarker discovery, therapeutic development and future clinical trials. - The partners also plan to broaden engagement with additional academic institutions, clinicians, patient advocacy groups and industry collaborators as the initiative expands. - JRBF is a UK-registered charity and U.S. tax-exempt 501(c)(3) nonprofit focused on research, awareness and support for individuals and families affected by NF1. - Curo 46 is a U.S.-based artificial intelligence, biotech and bioinformatics company focused on healthcare and biosciences. - Curo 46 develops AI-enabled platforms that integrate complex datasets to generate actionable insights for research and decision-making.

Between the lines: - The collaboration pairs patient advocacy with academic medicine and commercial AI, a structure that can help move rare-disease research from data collection toward usable clinical tools. - The emphasis on clinically governed and responsible health AI suggests the partners want the platform to be credible for eventual trial use, not just exploratory research. - Joel Bell said the mission is personal to his family and that JRBF was founded in memory of Joanna Ruth Bell, whose experience with NF1 inspired the foundation’s work. - AJ Rosenthal said the partnership could serve as a model for rare disease exploration. - Philip R.O. Payne said WashU Medicine sees the effort as a way to accelerate therapeutic development, improve patient stratification and enable precision clinical trials.

What’s next: - The partners will build out the scalable data framework and look to add more collaborators over time. - Future work is expected to focus on integrating larger datasets and turning the platform into a foundation for biomarker discovery and clinical-trial planning. - The collaboration could open the door to broader rare-disease applications if the model proves effective.

The bottom line: - JRBF, General Genomics and WashU Medicine are trying to turn fragmented NF1 data into a research engine that can support precision medicine and faster treatment development. - More information is available on Joanna Ruth Bell Foundation’s social page.